Real-World Prevalence Of Homologous Recombination Repair Gene (Brca1/2 And Atm) Mutations (Hrrm) In Patients (Pts) With Advanced Prostate Cancer (Apc) As Detected By Comprehensive Genomic Profiling (Cgp) Of Circulating Cell-Free Dna (Cfdna)

Nicolas Sayegh,Umang Swami,Pedro C. Barata,Michael B. Lilly,Roberto Nussenzveig,Chuck Hensel,Alan Haruo Bryce,Mehmet Asim Bilen,Elisabeth I. Heath,Lakshminarayanan Nandagopal,Rohan Garje,Philip James Saylor,Hani M. Babiker,Daniel A. Vaena,Manish Kohli,Sumanta K. Pal,A. Oliver Sartor,Neeraj Agarwal

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览8

暂无评分

摘要

256Background: PARP inhibitors, olaparib and rucaparib recently improved survival outcomes (in the Profound and Triton-2 trials) in pts with aPC harboring HRRm. Notably, ~35% of pts screened for th...

查看译文

关键词

Rucaparib,Olaparib,Homologous recombination,Prostate cancer,Circulating Cell-Free DNA,Gene,Cancer research,Poly ADP ribose polymerase,Medicine,Genomic profiling

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要